German pharmaceutical and chemicals company Bayer AG (BAYN.XE) said Monday that it has received U.S. approval for Staxyn, a new formulation of its erectile dysfunction treatment Levitra.

MAIN FACTS:

-Staxyn is a tablet that disintegrates on the tongue without liquid.

-GlaxoSmithKline (GSK) and Merck & Co. Inc. (MRK), Bayer's U.S. marketing partners, expect to make the medicine available by prescription later this year.

-Bayer has submitted the product for marketing authorization in Europe and expects to receive approval in 2010.

 
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Bayer (TG:BAYN)
Historical Stock Chart
From Nov 2023 to Dec 2023 Click Here for more Bayer Charts.
Bayer (TG:BAYN)
Historical Stock Chart
From Dec 2022 to Dec 2023 Click Here for more Bayer Charts.